<?xml version="1.0" encoding="UTF-8"?>
<p>The bioactive metabolite β-caryophyllene also produced a significant reduction in the nociceptive behavior all along the temporal course (
 <xref ref-type="fig" rid="molecules-25-00675-f004">Figure 4</xref>A–C). These results allowed observing that β-caryophyllene (10 mg/kg) produced almost a 95% analgesic-like effect in the neurogenic phase (
 <xref ref-type="fig" rid="molecules-25-00675-f004">Figure 4</xref>B). Regarding the inflammatory phase (
 <xref ref-type="fig" rid="molecules-25-00675-f004">Figure 4</xref>C), β-caryophyllene at 5.62 and 10 mg/kg produced antinociception of 34% and 73%, respectively.
</p>
